Innovations in Soft Tissue Sarcoma Diagnosis and Treatment (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 34
Special Issue Editors
Interests: sarcoma; gene therapy; natural killer cell therapy; immune and cell-cycle checkpoint inhibitors; tumor targeting
Interests: sarcoma; gene therapy; natural killer cell therapy; immune and cell-cycle checkpoint inhibitors; tumor targeting
Special Issues, Collections and Topics in MDPI journals
Interests: cancer gene therapy; targeted gene delivery; cyclin G1; oncogenic drivers along the CCNG1 pathway; retroviral vector cloning; targeting pharmaceutical agents to injured tissues
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous Special Issue, “Innovations in Soft Tissue Sarcoma Diagnosis and Treatment” (https://www.mdpi.com/journal/cancers/special_issues/Soft_Tissue_Sarcoma_Diagnosis).
Recent advances in genetic screening, molecular profiling, targeted therapy, gene therapy, and immunotherapy for soft tissue sarcomas (STS) have evoked increasing optimism in the medical and scientific community. Hence, we must reflect on the many faces of STS and current innovations in its diagnosis and treatment. STS is a rare cancer involving mesodermal tissues. Surgical resection is the standard of care for localized disease; however, the recurrence rate is high and the prognosis for advanced STS is poor, with a median survival of 8–13 months.
This Special Issue, entitled “Innovations in Soft Tissue Sarcoma Diagnosis and Treatment (Volume II)”, will include review articles and original clinical and translational research articles that are hypothesis-generating toward the development of precision medicine for STS.
Dr. Erlinda M. Gordon
Dr. Sant P. Chawla
Dr. Frederick L. Hall
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- soft tissue sarcoma
- gene therapy
- natural killer cell therapy
- immune and cell cycle checkpoint inhibitors
- targeted therapy
